ACT Biotech Inc.
This article was originally published in Start Up
Executive Summary
Oncology-focused ACT Biotech acquired its oral kinase programs from Bayer when it merged with Schering. The start-up's lead compound is telatinib, a potent and selective orally available inhibitor of three receptor tyrosine kinases. According to ACT, it is the most selective kinase inhibitor yet developed. That selectivity imparts an excellent safety profile, which makes it well tolerated at high, continuous doses. The candidate also has no overlapping side effects with other chemotherapy drugs.